

## **Response to reviewers:**

### **Reviewer 1**

Yang R et al. reported a case of programmed cell death-ligand 1 (PD-L1) expression positive MIBC with squamous and glandular differentiation, who refused total cystectomy. The patient received combination treatment with chemotherapy and immunotherapy after successful transurethral resection of the bladder tumor (TURBT). A marked response to combination treatment was achieved and the patient successfully preserved bladder function. Not only the case is presented thoroughly, the article is also written in good scientific and English style and could be published in its current format. However, I would like to suggest listing the NGS results and the mutated genes in a Table and compare those findings in a more comprehensive way in the discussion.

**Response:** We have listed the NGS results and the mutated genes in a Table and compare those findings in the discussion.

### **Reviewer 2**

The authors are showing a case report about a patient who achieved bladder preservation and has been tumor-free for more than two years upon receiving a combination of chemotherapy (cisplatin/gemcitabine) and immunotherapy (tislelizumab) treatment. The manuscript is very well written and the case is clearly and sufficiently presented. I highly recommend this paper for publication as it opens a highly channel for the application of combined chemo/immuno therapy that many basic and translational research studies have been recommending for many years. It provides a real-world evidence that needs to be further applied and confirmed by stronger and wider studies. The manuscript requires English revision.

**Response:** The manuscript has been taken for language revision and we have offered the certificate to the editors.